Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;62(11):1495-1503.
doi: 10.2967/jnumed.120.261016. Epub 2021 Jul 22.

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

Valery Radchenko  1   2 , Alfred Morgenstern  3 , Amir R Jalilian  4 , Caterina F Ramogida  5   6 , Cathy Cutler  7 , Charlotte Duchemin  8   9 , Cornelia Hoehr  5 , Ferrid Haddad  10 , Frank Bruchertseifer  3 , Haavar Gausemel  11 , Hua Yang  5 , Joao Alberto Osso  4 , Kohshin Washiyama  12 , Kenneth Czerwinski  13 , Kirsten Leufgen  14 , Marek Pruszyński  15   16 , Olga Valzdorf  17 , Patrick Causey  18 , Paul Schaffer  5 , Randy Perron  19 , Samsonov Maxim  20 , D Scott Wilbur  21 , Thierry Stora  8 , Yawen Li  21
Affiliations
Review

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

Valery Radchenko et al. J Nucl Med. 2021 Nov.

Erratum in

  • Errata.
    [No authors listed] [No authors listed] J Nucl Med. 2022 Jul;63(7):100-1000. J Nucl Med. 2022. PMID: 35772958 Free PMC article. No abstract available.

Abstract

Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides, The Journal of Nuclear Medicine will provide a comprehensive assessment of the field.

Keywords: 211At; 212Pb/212Bi; 225Ac/213Bi; 227Th/223Ra; production and supply of radionuclides; targeted α-therapy.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Decay scheme of 227Ac.
FIGURE 2.
FIGURE 2.
Decay scheme of 233U.
FIGURE 3.
FIGURE 3.
Decay scheme of 211At.
FIGURE 4.
FIGURE 4.
Direct and indirect production routes of 211At. 211Rn can also be produced by spallation of actinide targets (uranium or thorium) induced by high-energy protons (reaction not shown).
FIGURE 5.
FIGURE 5.
Decay scheme of 232Th and 232U.
FIGURE 6.
FIGURE 6.
Decay scheme of 230Pa.
FIGURE 7.
FIGURE 7.
Decay scheme of 149Tb.
See this image and copyright information in PMC

References

    1. Nicolas GP, Morgenstern A, Schottelius M, Fani M. New developments in peptide receptor radionuclide therapy. J Nucl Med. 2019;60:167–171. - PubMed
    1. Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer. News release. Novartis; March 23, 2021.
    1. Heinrich D, Bektic J, Bergman AM, et al. . The contemporary use of radium-223 in metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2017;16:e223–e231. - PubMed
    1. Makvandi M, Dupis E, Engle JW, et al. . Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018;13:189–203. - PubMed
    1. Morgenstern A, Abbas K, Bruchertseifer F, Apostolidis C. Production of alpha emitters for targeted alpha therapy. Curr Radiopharm. 2008;1:135–143.

MeSH terms

LinkOut - more resources